Viatris Inc. VTRS

NASDAQ US Health Care Pharmaceuticals

$20.49 ▲ +2.91% (+$0.58)

Index member: S&P 500

🎯 52W High ⬆️ Above Yest. High

Open $20.11

Prev Close $19.91

Day Range $19.90 – $20.53

52W Range $9.92 – $19.96

Market Cap $21.86B

Beta 0.85

Div Yield 5.09%

EPS (TTM) $-0.36

📋 Company Profile

Industry	Pharmaceuticals
Sector	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1973-02-01
Shares Out.	1,148,590,000
Website	viatris.com/en ↗
Phone	13026587581
Employees	30,000
Revenue	$3.75B
Gross Profit	$1.44B
Net Income	-$325.3M
Free Cash Flow	$2.11B
Total Assets	$34.68B
Total Liabilities	$21.00B
Equity	$13.69B

About Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.

Viatris Inc. is a publicly traded company under the ticker symbol VTRS on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.